Tel Aviv - Delayed Quote ILA

Epitomee Medical Ltd (EPIT.TA)

Compare
930.00
-22.50
(-2.36%)
As of 12:54:04 PM GMT+2. Market Open.
Loading Chart for EPIT.TA
DELL
  • Previous Close 952.50
  • Open 952.50
  • Bid 930.00 x --
  • Ask 933.00 x --
  • Day's Range 925.00 - 952.50
  • 52 Week Range 249.40 - 1,570.00
  • Volume 16,887
  • Avg. Volume 116,571
  • Market Cap (intraday) 277.253M
  • Beta (5Y Monthly) 0.84
  • PE Ratio (TTM) --
  • EPS (TTM) -0.74
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. Its capsule is used for weight management, waist circumference reduction, and cardiovascular risk factors reduction. Epitomee Medical Ltd has a strategic partnership with Nestlé Health Science S.A. for the development and commercialization of the weight loss capsule. The company was incorporated in 2005 and is based in Caesarea, Israel.

www.epitomeemedical.com

42

Full Time Employees

December 31

Fiscal Year Ends

Recent News: EPIT.TA

View More

Performance Overview: EPIT.TA

Trailing total returns as of 1/19/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

EPIT.TA
0.08%
TA-125
8.30%

1-Year Return

EPIT.TA
144.29%
TA-125
38.78%

3-Year Return

EPIT.TA
69.00%
TA-125
22.43%

5-Year Return

EPIT.TA
62.90%
TA-125
56.32%

Compare To: EPIT.TA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EPIT.TA

View More

Valuation Measures

Annual
As of 1/16/2025
  • Market Cap

    283.96M

  • Enterprise Value

    194.04M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.81

  • Price/Book (mrq)

    2.63

  • Enterprise Value/Revenue

    5.38

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -60.35%

  • Return on Assets (ttm)

    1.07%

  • Return on Equity (ttm)

    -18.64%

  • Revenue (ttm)

    10M

  • Net Income Avi to Common (ttm)

    -6.04M

  • Diluted EPS (ttm)

    -0.74

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    29.14M

  • Total Debt/Equity (mrq)

    14.17%

  • Levered Free Cash Flow (ttm)

    -1.48M

Research Analysis: EPIT.TA

View More

Company Insights: EPIT.TA

Research Reports: EPIT.TA

View More

People Also Watch